Approved for use through 07/31/2012. OMB 0985-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OC COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number;

STATEMENT UNDER 37 CER 3 73(b)

Applicant/Patent Owner: William Stern
Application No./Patent No.: RE40,812 Filed/Issue Date: June 30, 2009
Titled: Nasal Calcitonin Formulation
Unigene Laboratories, Inc. , a corporation (Nane of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government egency, etc.
states that it is:
1. X the assignee of the entire right, title, and interest in;
an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is
3.
the patent application/patent identified above, by virtue of either:
A. [X] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 011702 , Frame 0952 , or for which a copy therefore is attached.
Copy therefore is attached. OR
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: To:
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
2. From: To:
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
3. From: To:
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The understapped trinose title is supplied below) is authorized to act on behalf of the assignee.
\$///une 5/24/11
Signature Date
Vice President, Corporate Affairs and General Counse Gregory T. Mayes Unigene Laboratories, Inc.
Printed or Typed Name Title
This collection of information in manifed by 27 CER 2 72(b). The information is manifed to the collection of information in manifed by 27 CER 2 72(b).

This collection of information is required by 37 CFR 3,73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Informetion Officer, U.S. Patent and Tredemark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.